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http://dx.doi.org/10.1016/j.jacl.2015.1Abstract: Cardiovascular (CV) disease is a leading cause of death worldwide, accounting for
approximately 31.4% of deaths globally in 2012. It is estimated that, from 1980 to 2000, reduction
in total cholesterol accounted for a 33% decrease in coronary heart disease (CHD) deaths in the United
States. In other developed countries, similar decreases in CHD deaths (ranging from 19%–46%) have
been attributed to reduction in total cholesterol. Low-density lipoprotein cholesterol (LDL-C) has now
largely replaced total cholesterol as a risk marker and the primary treatment target for hyperlipidemia.
Reduction in LDL-C levels by statin-based therapies has been demonstrated to result in a reduction in
the risk of nonfatal CV events and mortality in a continuous and graded manner over a wide range of
baseline risk and LDL-C levels. This article provides a review of (1) the relationship between LDL-C
and CV risk from a biologic, epidemiologic, and genetic standpoint; (2) evidence-based strategies for
LDL-C lowering; (3) lipid-management guidelines; (4) new strategies to further reduce CV risk
through LDL-C lowering; and (5) population-level and health-system initiatives aimed at identifying,
treating, and lowering lifetime LDL-C exposure.
 2015 National Lipid Association. This is an open access article under the CCBY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
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1.0102012.1 In developed countries, age-adjusted CV mortality
rates are declining, but CV disease remains the leading cause
of mortality due to rapid aging of the population. In
low-income to middle-income countries, both age-adjusted
CV mortality rates and aging of these populations are
contributing to a rapid increase in CV mortality.2 Data from
2010 demonstrate that CV disease accounted for 31.9% of
US deaths, with ischemic heart disease and stroke accounting
for the vast majority (total 27.6%; 21.1%, and 6.5%,
respectively). In the United States, the resultant direct and
indirect annual costs were estimated to be $240.9 billion.3,4nder the CC BY-NC-ND license (http://creativecommons.org/licenses/
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in 2010, with a 22% increase expected by 2030.5
A large, worldwide study found that among all modifi-
able risk factors, abnormal lipid levels were associated with
the highest population attributable risk (approximately
50%) for the occurrence of myocardial infarction (MI;
Table 1).6
This is due to their prevalence and strong, independent
association with the risk of MI. In western countries,
lifestyle interventions and evidence-based therapies,
including those focused on hypercholesterolemia, have
led to a reduction in CV risk on a population level. In a
series of studies covering the 1980 to 2010 time period in
the United States, Canada, and Europe (Table 2), it was
estimated that 19%–46% of the total reduction in the rate
of coronary heart disease (CHD) mortality was explained
by a reduction in total cholesterol levels attributed to
lifestyle changes and pharmacologic treatment.7–16
Low-density lipoprotein cholesterol (LDL-C) has now
largely replaced total cholesterol as the primary lipid
measurement for evaluation of risk due to atherogenic
lipoproteins. LDL-C is a measure of the total cholesterol
content of LDL particles, reflecting both the number of LDL
particles and their individual cholesterol content. Most
current guidelines include LDL-C as a primary target for
initiating and adjusting lipid-lowering interventions.17–20
In addition, more effective and/or scalable LDL-C
reduction strategies are under investigation for risk
reduction in both primary and secondary prevention. This
article provides a review of (1) the relationship between
LDL-C and CV risk from a biologic, epidemiologic, and
genetic standpoint; (2) evidence-based strategies for
LDL-C lowering; (3) lipid-management guidelines; (4)
new strategies to further reduce CV risk through LDL-C
lowering; and (5) population level and health-systemTable 1 Population attributable risk for the incidence of
acute MI for modifiable risk factors*
Risk factor
Population
attributable
risk (%)‡
Abnormal lipids† 49.2
Tobacco consumption (current smoker) 35.7
Psychosocial 32.5
Abdominal obesity 20.1
Hypertension 17.9
Diet (lack of daily vegetable and fruits) 13.7
Physical activity 12.2
Diabetes 9.9
Alcohol intake 6.7
Apo, apolipoprotein.
*Based on the INTERHEART study by Yusuf et al., 2004.6
†Estimated by apoB/apoA1 ratio (fifth quintile compared to first).
‡Population attributable risk percentages do not add up to 100%
for a combination of risk factors, because an MI can be simultaneously
attributed to .1 risk factor and thus be counted twice.initiatives aimed at identifying, treating, and lowering
lifetime LDL-C exposure.Relationship between LDL and CV risk
Cholesterol is circulated in the body’s aqueous
extracellular environment by 5 major types of lipoprotein
(chylomicrons, very low-density lipoprotein [VLDL],
intermediate-density lipoprotein [IDL], LDL, and high-
density lipoprotein [HDL]). The liver serves as the key
organ for cholesterol metabolism and regulation of
plasma levels of cholesterol. The process of LDL forma-
tion begins when intrahepatic cholesterol, either from gut
absorption or de novo synthesis, is repackaged by the
liver (along with proteins, triglycerides, and phospho-
lipids) into VLDL. VLDL then enters the circulation
and is converted by lipoprotein lipase and cholesteryl
ester transfer protein (CETP) into more cholesterol-
enriched species, first IDL and then LDL. The liver
regulates the concentration of these circulating lipoprotein
species primarily by their clearance through LDL
receptors on the hepatic surface.21
Circulating LDL particles are able to penetrate the
endothelium of arterial walls and become oxidized,
promote inflammation, and drive injury to the overlying
endothelium and surrounding smooth muscle cells.22
Persistent elevations in circulating LDL-C have been
directly linked to progression from early-stage fatty streaks
to advanced-stage, lipid-rich plaques. For example, LDL
receptor-deficient mice (i.e., unable to clear LDL from
the circulation) have elevated LDL-C and consequently
develop severe atherosclerosis.23 Conversely, mice with
virtually no LDL-C do not develop atherosclerosis
irrespective of diet and other CHD risk factors.24
Epidemiologic investigations have validated LDL-C as
an independent predictor of CV risk. The Framingham
Heart Study demonstrated that men and women were .1.5
times more likely to develop clinically significant CHD if
their LDL-C was .160 mg/dL compared to a reference
population with LDL-C ,130 mg/dL.25 In the Atheroscle-
rosis Risk in Communities (ARIC) study, the risk of an
incident CHD event was elevated by approximately 40%
for every 39 mg/dL incremental increase in LDL-C.26
Genetic analyses have demonstrated that a number of
single-nucleotide polymorphisms (SNPs) are associatedwith
LDL-C and CV risk. A study by Willer et al. demonstrated
that SNPs of genes such asPCSK9,APOE,APOB, and LDLR
that result in elevated LDL-C are also associated with
elevated CV risk.27 Another study by Kathiresan et al.
demonstrated that specific SNPs of genes such as PCSK9,
APOE, APOB, HMGCR, and LDLR result in decreased
LDL-C and are associated with decreased CV risk.28 These
associations have been validated in other investigations.29–32
Genetic studies suggest that CV risk is associated not
just with the absolute concentration of LDL-C but also with
the duration of exposure. Certain genetic mutations
Table 2 Studies assessing the attributable risk reduction in CHD mortality driven by statins and other changes affecting total
cholesterol levels
Study Country Time period
Attributable risk reduction* (%)
Statin treatment Other causes Total
Bjorck et al., 20097 Sweden 1986–2002 6.2 39.5 45.7
Bandosz et al., 20128 Poland 1991–2005 3.4 39.0 42.4
Wijeysundera et al., 20109 Canada 1994–2005 15.4 22.8 38.2
Flores-Mateo et al., 201110 Spain 1988–2005 5.6 31.1 36.7
Hughes et al., 201311 Northern Ireland 1987–2007 8.7 25.8 34.5
Ford et al., 200712 USA 1980–2000 8.5 24.2 32.7
Aspelund et al., 201013 Iceland 1981–2006 0.5 32.0 32.5
Palmieri et al., 201014 Italy 1980–2000 6.4 23.4 29.8
Hotchkiss et al., 201415 Scotland 2000–2010 13.3 8.9 22.2
Bajekal et al., 201216 England 2000–2007 13.9 5.5 19.4
CHD, coronary heart disease.
*Represents the attributable reduction in CHD mortality risk from changes in total cholesterol via statin treatment and other (e.g., diet related)
causes.
474 Journal of Clinical Lipidology, Vol 10, No 3, June 2016resulting in lower LDL-C have demonstrated a greater
impact on CV risk reduction (Fig. 1) than similar levels of
statin-induced LDL-C reduction, presumably because statin
treatment is typically initiated later in life.
For example, sequence variation in the proprotein
convertase subtilisin/kexin type 9 (PCSK9) gene was
associated with a 15% reduction in LDL-C and a 47%
reduction in CHD risk. Nonsense mutations of this gene
were associated with a 28% reduction in LDL-C and an
88% reduction in CHD risk.33 Naturally occurring,
inactivating mutations of the Niemann-pick C1-like 1
(NPC1L1) gene in humans were associated with LDL-C
reductions of 12 mg/dL and a 53% reduction in CHD
risk.29 A meta-analysis by Ference et al. demonstrated
that 9 polymorphisms in 6 different genes were associated
with a 54% reduction in CHD risk per 1 mmol/L reduction
in LDL-C.34 In comparison, only a 24% reduction in major
coronary events with statin therapy over a median follow-
up of 4.8 years has been demonstrated.35 The significance
of the chronicity of LDL-C exposure is also supported by
recent epidemiologic analyses, which suggest that strate-
gies for earlier initiation and prolonged LDL-C lowering
might yield striking benefits for reducing CV risk.36,37
The association of LDL with CV risk is also supported
by data from alternative measures of atherogenic lipopro-
teins. For example, at identical LDL-C levels, measurement
of the number of circulating LDL particles has important
prognostic value. A higher number of smaller LDL
particles is associated with higher CV risk.38 In one study
of approximately 7000 participants without CV disease at
baseline, LDL-attributable atherosclerotic risk was better
indicated by LDL particle number when LDL-C and LDL
particle number were discordant.38 This may be due to
the enhanced delivery of cholesterol to an atheroma by
greater numbers of smaller LDL particles.39 Furthermore,
small dense LDL particles are more susceptible to oxida-
tion and experience-decreased uptake by LDL receptors.40Other laboratory markers of atherogenic lipoproteins
correlate with LDL-C and also demonstrate similar
relationships with CV risk. Both apolipoprotein (apo) B
and non–high-density lipoprotein cholesterol (non-HDL-C)
measure the contribution to atherogenic risk from the total
number of atherogenic particles, including LDL, VLDL,
IDL, chylomicrons, and lipoprotein(a).19 The total number of
apoB particles represents the total number of atherogenic
lipoproteins, whereas non-HDL-C measures the total
cholesterol content carried by these particles. These assays
may be especially useful for patients with elevated
triglycerides, who derive a greater proportion of their CV
risk from triglyceride-rich particles than those with lower
triglyceride levels. In a meta-analysis of epidemiologic
studies of 3 atherogenic biomarkers, apoB was found to be
the best CV risk predictor, followed by non-HDL-C and
LDL-C.41 In an analysis of statin-treated patients, non-
HDL-C was found to be the best predictor of CV risk when
compared to apoB and LDL-C.42 These findings have led
to the incorporation of non-HDL-C and apoB as primary or
secondary treatment targets in recent guidelines. Although
the roles of LDL particle number, apoB, non-HDL-C, or
other measures such as the ratio of apoB/apoA1 for CV
risk assessment are increasing, LDL-C remains the
measure most commonly used for clinical trials and in
clinical care.Evidence-based strategies for LDL-C
lowering
A number of approaches for LDL-C lowering have been
well studied. These include lifestyle interventions, phar-
macologic treatment, intestinal bypass surgery, and lipid
apheresis. Below, we focus on the evidence for lifestyle
interventions and pharmacologic treatment as well as their
influence on cholesterol management guidelines.
Figure 1 Association between absolute change in LDL-C levels over lifetime due to genetic variation and the change in relative risk for
CHD.
Based on data from Willer et al., 2008,27 Myocardial Infarction Genetics Consortium et al., 2014,29 Linsel-Nitschke et al., 2008,30 Cohen
et al., 2006,33 Ference et al., 2012,34 and Stender et al., 201431 The figure has been limited to data from these studies regarding mutations
with significant associations with both LDL-C levels and coronary outcomes. The studies were reviewed for duplicate reporting of data.
Labels in the graph represent genes; repeated observations (e.g. LDLR) represent different SNPs. Where OR or HR were reported, change
in relative risk was approximated as OR – 1 or HR – 1. The solid line represents estimated relationship via linear unweighted regression
(Y 5 0.0259 ! X 1 0.0173).
CHD, coronary heart disease; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; SNP, single-nucleotide
polymorphism.
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Societal changes, largely resulting from agricultural and
industrial expansion, have led to higher population LDL-C
levels. Evidence from hunter-gatherers has demonstrated
that these populations have LDL-C levels typically ranging
from 50 to 75 mg/dL. These populations are characterized
by an absence of atherosclerosis, even in individuals living
up to 8 decades. Furthermore, healthy, wild, adult primates
have LDL levels of approximately 40 to 80 mg/dL.43,44 In
contrast, the currently accepted ‘‘normal’’ LDL-C range in
Westernized societies is 100 to 160 mg/dL. This suggests
that LDL-C levels in Western societies are grossly above
the true physiologic range.45
Development and promotion of lifestyle recommenda-
tions to reduce CHD, initiated in the second half of the 20thcentury, have played a critical role in the decline of death
from CHD.7–16 One striking example began with a
comprehensive, community pilot project conducted in
North Karelia, Finland. In the late 1960s, men from this
region had the highest CHD mortality rate in the world
predominantly due to consumption of saturated fats and
sodium, as well as smoking. Based on the results of the
pilot project and implementation of its findings through
national policy and health promotion initiatives (e.g., health
education, development of a domestic vegetable oil
industry) across Finland, a shift in the nationwide
population distribution of cholesterol, blood pressure, and
smoking was achieved. Reductions in saturated fat
consumption led to a 60 mg/dL decline in mean national
total cholesterol levels. Over the course of 35 years, in
men aged 35 to 64 years, drastic reductions in
476 Journal of Clinical Lipidology, Vol 10, No 3, June 2016age-adjusted CHD mortality rates of 85% in North Karelia
and 80% across Finland (down to 100 CHD deaths per
100,000 individuals) were achieved. Approximately 75%
of this reduction was explained by a decrease in the 3 tar-
geted risk factors. Among these, lowering of cholesterol ac-
counted for most of the observed benefit.46,47
Cholesterol reduction can be achieved by a number of
other changes in dietary habits. A meta-analysis of 67
controlled studies demonstrated that 2 to 10 g per day of
dietary soluble fiber consumption reduces LDL-C by
2.2 mg/dL.48 Phytosterol consumption reduces LDL-C by
13 mg/dL for every 2.15 g consumed daily.49 Nut consump-
tion (67 g daily) decreases LDL-C by 10.2 mg/dL and daily
soy isoflavone consumption by 5 mg/dL.50,51 Small LDL
particle number has also been shown to be inversely
correlated with crude-fiber consumption and positively
related to dietary cholesterol intake, high-carbohydrate
(and particularly high glycemic index) diets, and trans-
fatty acid (TFA) consumption.52,53 TFA consumption is
associated with significantly higher LDL-C levels but has
been decreasing over the past 3 decades due to efforts to
eliminate industrial TFA in foods.54
Beyond individual foods, comprehensive diets such as
the Mediterranean diet, which is comprised of primarily
fruits, vegetables, legumes, grains, nuts, and olive oil, have
been shown to reduce LDL-C by 10% after 5 weeks.55 A
recent study found that adults who followed the Mediterra-
nean diet over 10 years were 47% less likely to develop
heart disease compared to similar adults who did not follow
this diet.56 The more stringent Ornish diet has been shown
to reduce LDL-C by 37%, although adherence is extremely
difficult to achieve.57
Exercise training, independent of weight loss, does not
significantly reduce LDL-C levels.58–61 However, random-
ized studies indicate that physical activity results in a
decrease in small LDL particle number.62–64 Thus, a shift
from higher numbers of smaller, more atherogenic particles
to fewer, larger particles, may partially explain the
reduction in CV risk associated with physical activity.65
Overall, an improved diet and exercise regimen most
commonly lowers LDL-C by 10%–15%.66 Consistent with
genetic data demonstrating large CV risk reductions from
chronic small to moderate reductions in LDL-C, improved
dietary habits across the population beginning very early in
life can yield large reductions in CHD and CHD-related
healthcare spending. New research focusing on developing
better dietary habits in children will be discussed later in the
review.
Nonstatin pharmacologic therapies
In addition to lifestyle changes, LDL-C lowering has been
advanced by drug-based therapy. The first pharmacologic
treatment for LDL-C lowering, which demonstrated a
significant reduction on a primary CV endpoint was chole-
styramine, a bile acid sequestrant. In the Lipid Research
Clinics Coronary Primary Prevention Trial (LRC-CPPT),cholestyramine lowered LDL-C levels by 12% (22 mg/dL)
compared with placebo, with a relative reduction in the risk
of nonfatal MI or CHD death by 19%.67 The relative CV risk
reduction per mg/dL reduction in LDL-C from this trial is
consistent with the subsequent findings from the large
meta-analysis of statin trials from the Cholesterol Treatment
Trialists Collaboration (CTT).35 No large, randomized trials
have tested whether bile acid sequestrants would reduce CV
events on top of statin therapy in a primary or secondary
prevention population.
Before the statin era, niacin, which influences VLDL
metabolism and lowers LDL-C, was compared to placebo
in the Coronary Drug Project.68 Although niacin did not
reduce total mortality (primary endpoint), it did reduce
nonfatal MI (secondary endpoint), which may be related
to the 26 mg/dL (10.1%) reduction in total cholesterol. A
post-trial exploratory analysis conducted 9 years after the
completion of the trial found that these effects were
associated with reduced mortality.
The role of niacin in patients well-treated with statins
remains unclear. In the HPS2-THRIVE trial, the addition of
extended-release niacin to a background of statin therapy
reduced LDL-C and raised HDL-C levels by 10 mg/dL
(15.6%) and 6 mg/dL (13.6%), respectively, compared to
placebo. Niacin did not reduce the risk of major CV events
and was accompanied by a range of serious adverse
events.69 The results of the much smaller AIM-HIGH trial
also failed to demonstrate a CV benefit for niacin on top of
statins.70 A plausible explanation for the nonsignificant CV
risk reduction findings in these trials is that niacin only
resulted in a modest absolute reduction in LDL-C because
the baseline LDL-C was well-controlled (e.g.,,80 mg/dL).
To date, it is unknown whether niacin results in a clinical
benefit when added to statin therapy in patients with higher
baseline LDL-C levels.
Ezetimibe inhibits the function of the NPC1L1 protein,
which is responsible for transportation of dietary choles-
terol from the gut lumen to intestinal enterocytes, thus
reducing the absorption of dietary cholesterol.71,72
Although ezetimibe was approved by the Food and Drug
Administration (FDA) to lower LDL-C in 2002, its efficacy
in reducing CV outcomes was only recently demonstrated.
The Improved Reduction of Outcomes: Vytorin Efficacy
International Trial (IMPROVE-IT) studied ezetimibe in a
post-acute coronary syndrome (ACS) population with
well-controlled LDL-C on background statin therapy.
Ezetimibe resulted in a 15.8 mg/dL (23.9%) reduction in
LDL-C levels and a 6.4% relative risk reduction in the
primary composite endpoint of CV death, major coronary
events, or nonfatal stroke at 7 years, as well as a 13%
relative reduction in risk of any MI and 7.2% relative risk
reduction in rate of major vascular events (MVE).73 The
findings from IMPROVE-IT suggest that the ezetimibe-
induced CV risk reduction per mg/dL LDL-C reduction is
similar to statins. Ezetimibe is the first LDL-C-lowering
drug to demonstrate a reduction in CVoutcomes in patients
well-treated with statins.
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Statins inhibit the rate-limiting enzyme, HMG-CoA
reductase, in the synthesis pathway of cholesterol.
This results in lower intrahepatic cholesterol and an
up-regulation of hepatic cell surface LDL receptors,
resulting in enhanced receptor-mediated uptake of LDL
and other apoB-containing lipoproteins from the circula-
tion. Evidence supports their effectiveness in lowering
coronary, cerebrovascular, and peripheral vascular events.
Primary prevention trials with statins have demonstrated a
CVoutcomes benefit in patients with hypercholesterolemia,
diabetesmellitus, chronic kidneydisease, and normal LDL-C
(100 to 160 mg/dL) in the setting of other risk factors
(Table 3).74–82 A meta-analysis of the lowest risk subjects
from statin trials found that 1 mmol/L (w39 mg/dL) of
LDL-C reduction was associated with 38% and 31%
decreases in the relative risk of MVE (nonfatal MI, coronary
death, coronary revascularization, or stroke) in subgroups of
5-year predicted risk,5% and$5% to,10%, respectively.
When these 2 subgroups were pooled, the absolute reduction
in MVE was 11 per 1000 over 5 years.35
The benefit of statin therapy in reducing CV events in
patients with known atherosclerotic CV disease has been
well-established (Table 3).83–93 In addition, more intensive
(i.e., potent) statin regimens have been found to have greater
efficacy compared to less-intensive regimens. The CTT
meta-analysis demonstrated that 1 mmol/L (w39 mg/dL)
reduction in LDL-C resulted in a 10% relative reduction in
all-cause mortality and a 21% relative reduction in MVE
for statins vs placebo. Decreases in the rate of individual end-
points per 1 mmol/L LDL-C reductions were major coronary
events (24%), coronary revascularization (24%), ischemic
stroke (20%), and any stroke (15%). Intensive statin
($50%LDL-C lowering) vs less intensive (,50%) regimens
further reduced LDL-C by 0.51 mmol/L (20 mg/dL) and led
to another 15% relative risk reduction in MVE. These rela-
tionships were found to be consistent for all patient subtypes
studied and indicated no threshold beyond which LDL-C
lowering would not provide benefit (including ,2 mmol/L
[w80 mg/dL]), findings consistent with other large-scale
studies.6,94 The efficacy of statins on CV outcomes also
appears to be consistent in both primary and secondary
prevention populations across racial, ethnic, and regional
practice differences.35,94 In another CTT meta-analysis,
statins were found to reduce LDL-C similarly in both men
and women, with similar proportional reductions in MVEs.
However, in the subgroup with no prior CV disease, the
relative risk reduction in women was found to be lower
compared with men (15% and 28%, respectively per
1 mmol/L LDL-C reduction).95
Statin adverse effects
Statins have also been evaluated for potential long-term
adverse effects. Estimates of statin-related adverse
events differ between randomized trials and observationalstudies, likely due to differences in patient selection. In
randomized trials, elderly individuals, subjects with multi-
ple comorbidities or on multiple medications, and women
are generally excluded or under-enrolled despite being
prescribed statins in clinical practice. Although observa-
tional trials have limitations, they provide useful data
regarding adverse events in clinical practice.96
Statins have been reported to increase the incidence of
nonserious musculoskeletal side effects (e.g., myalgia
without elevation in creatine kinase) in uncontrolled
observational studies (up to 20%), although this has not
been detected in randomized, double-blinded, clinical
trials.96 Rhabdomyolysis occurs in an excess of 4 cases
per 10,000 participants in intensive vs less-intensive statin
trials, and only 1 case per 10,000 participants in
less-intensive vs placebo trials.94 Statin-induced transami-
nase elevation occurs at an excess rate of only 4.2 per
1000 patients and is reversible with dose reduction or
discontinuation.97 Past statin-related safety concerns
including malignancy and cognitive dysfunction have
been directly assessed using randomized trial data without
any suggestion of a causal relationship.98 Statin therapy is
associated with a slight increase in risk of new onset
diabetes. This relationship is dose-dependent, and in 1
meta-analysis, the risk of incident diabetes in participants
receiving intensive statin treatment was 12% (P . .05)
higher compared to moderate statin treatment.99 However,
the risk is low in absolute terms, and the CV benefits of
statin therapy likely outweigh risk even in low-risk
patients.100,101Lipid-management guidelines
Guidelines offer practical recommendations for
achieving consistent, evidence-based care. Guidelines for
cholesterol management are available from the European
Society of Cardiology (ESC)/European Atherosclerosis
Society (EAS), American College of Cardiology (ACC)/
American Heart Association (AHA), National Lipid
Association (NLA), and International Atherosclerosis
Society (IAS) among other committees.17–20 These
documents identify similar patient groups that benefit
from LDL-C lowering. Below, we focus on the recommen-
dations from the ESC/EAS and ACC/AHA, as this
discussion illustrates the major differences between
available guidelines.
ESC/EAS guidelines, 2011
The ESC/EAS joint guidelines recommend lifestyle
modification as a component of all lipid-lowering treatment
strategies. They also recommend consideration of an
add-on pharmacologic treatment, with the intensity of
therapy adjusted to achieve specific LDL-C goals.18 Statin
use is principally recommended, although the addition of
bile acid sequestrants, cholesterol absorption inhibitors, or
Table 3 Summary of trials assessing the impact of statin therapy on LDL-C and cardiovascular outcomes
Study Population Drug (mg) PEP*
Mean
follow-up
(y)
Baseline
mean LDL
(mg/dL)†
Change relative to comparator arm
LDL-C
reduction
(%)
LDL-C
reduction
(mg/dL)
Absolute CV
risk reduction
Relative CV
risk reduction
5-Year
NNT‡
Primary prevention trials (statin vs placebo/usual care)
WOSCOPS74 6595 men aged 45–
64 y with high
cholesterol and no
history of MI in
West of Scotland
Pravastatin 40 Nonfatal MI, CHD
death
4.9 192 26% 49.9 2.4% (P , .001) 31% with
pravastatin
(P , .001)
41
AFCAPS/
TexCAPS75
6605 patients
without CHD and
average LDL-C
Lovastatin
20–40
MI, UA, sudden
cardiac death
5.2 150 25% 37.5 4.1% (P , .001) 37% with
lovastatin
(P , .001)
25
PROSPER76 5804 patients aged
70–82 y with
preexisting
vascular disease or
risk factors
Pravastatin 40 Nonfatal MI, stroke,
coronary death
3.2 146 34% 49.6 2.1% (P 5 .014) 15% with
pravastatin
(P 5 .014)
33
ALLHAT-LLT77 10,355 patients aged
$55 y with high
cholesterol, HTN,
and $1 other CHD
risk factors
Pravastatin 40 Nonfatal MI, CHD
death
4.8 146 17% 24.8 1.1% (P 5 .16) 9% with
pravastatin
(P 5 .16)
88
ASCOT-LLA78 10,305 patients with
HTN, $3 risk
factors, and lower
than average
cholesterol
Atorvastatin 10 Nonfatal MI, CHD
death
3.3 (median) 133 35% 46.4 3.4% (P 5 .0005) 36% with
atorvastatin
(P 5 .0005)
20
CARDS79 2838 patients with
type 2 diabetes
and without CV
disease or high
LDL-C
Atorvastatin 10 MI, UA with
hospitalization,
coronary
revascularization,
stroke,
resuscitated
cardiac arrest, CHD
death
3.9 (median) 117 40% 46.8 3.2% (P 5 .001) 37% with
atorvastatin
(P 5 .001)
25
ASPEN80 2410 patients with
type 2 diabetes
and LDL-C below
guideline targets
Atorvastatin 10 Nonfatal MI, UA with
hospitalization,
CABG, nonfatal
stroke,
resuscitated
cardiac arrest, CV
death
4.0 (median) 113 29% 32.8 1.3% (P 5 .34) 10% with
atorvastatin
(P 5 .34)
64
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MEGA81 7832 patients with
high cholesterol
and without CV
disease in Japan
Pravastatin
10–20
MI, angina, coronary
revascularization,
cardiac death
5.3 157 15% 23.2 1.7% (P 5 .01) 33% with
pravastatin
(P 5 .01)
62
JUPITER82 17,802 patients
without CV
disease, LDL-C
,130 mg/dL and
hsCRP .2 mg/L
Rosuvastatin 20 MI, UA with
hospitalization,
arterial
revascularization,
stroke, CV death
1.9 (median) 108 (median) 50% 54.0 0.59% (P , .00001) 44% with
rosuvastatin
(P , .00001)
66
Secondary prevention trials (statin vs placebo/usual care)
4S83 4444 patients with
CHD
Simvastatin
20–40
MI, resuscitated
cardiac arrest,
cardiac death
5.4 (median) 187 38% 71.1 9.0% (P , .00001) 34% with
simvastatin
(P , .00001)
12
CARE84 4159 patients with
average LDL-C and
history of MI
Pravastatin 40 Nonfatal MI, CHD
death
5.0 (median) 139 32% 44.5 3.0% (P 5 .003) 24% with
pravastatin
(P 5 .003)
33
LIPID85 9014 patients with
recent history of
MI or
hospitalization for
UA
Pravastatin 40 CHD death 6.1 150 (median) 25% 37.5 1.9% (P , .001) 24% with
pravastatin
(P , .001)
63
LIPS86 1677 patients after
first PCI with
stable angina, UA,
or silent ischemia
Fluvastatin 80 Nonfatal MI,
coronary
reintervention,
cardiac death
3.9 (median) 131 27% 35.4 5.3% (P 5 .01) 22% with
fluvastatin
(P 5 .01)
16
HPS87 20,536 patients with
CV disease,
diabetes, or HTN in
UK
Simvastatin 40 Nonfatal MI,
coronary or non-
coronary
revascularization,
stroke, CHD death
5.0 131 30% 38.7 5.4% (P , .001) 24% with
simvastatin
(P , .0001)
19
ALLIANCE88 2442 patients with
CHD and
hyperlipidemia
Atorvastatin
10–80
Nonfatal MI, UA with
hospitalization,
cardiac
revascularization,
resuscitated
cardiac arrest,
cardiac death
4.3 147 11% 16.2 3.5% (P 5 .02) 17% with
atorvastatin
(P 5 .02)
25
Secondary prevention trials (intensive vs less-intensive statin)
PROVE-IT89 4162 patients
recently
hospitalized for
ACS
Atorvastatin 80 vs
pravastatin 40
MI, UA with
hospitalization,
coronary
revascularization,
stroke, all-cause
death
2.0 124 29% 36.0 3.9% (P 5 .005) 16% with
atorvastatin
(P 5 .005)
15
(continued on next page)
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Table 3 (continued)
Study Population Drug (mg) PEP*
Mean
follow-up
(y)
Baseline
mean LDL
(mg/dL)†
Change relative to comparator arm
LDL-C
reduction
(%)
LDL-C
reduction
(mg/dL)
Absolute CV
risk reduction
Relative CV
risk reduction
5-Year
NNT‡
A to Z90 4497 patients after
ACS
Simvastatin 40 for
1 month then
simvastatin 80 vs
placebo for
1 month then
simvastatin 20
Nonfatal MI,
readmission for
ACS, stroke, CV
death
2.0 (median) 122 11% 13.4 2.3% (P 5 .14) 11% with
simvastatin
only (P 5 .14)
24
TNT91 10,001 patients with
stable CHD
Atorvastatin 80 vs
atorvastatin 10
Nonfatal MI,
resuscitated
cardiac arrest,
stroke, CHD death
4.9 (median) 152 15% 22.8 2.2% (P , .001) 22% with
atorvastatin
80 mg
(P , .001)
45
IDEAL92 8888 patients with a
history of MI
Atorvastatin 40–80
vs simvastatin
20–40
Nonfatal MI,
resuscitated
cardiac arrest,
coronary death
4.8 (median) 157 16% 25.1 1.1% (P 5 .07) 11% with
atorvastatin
(P 5 .07)
88
SEARCH93 12,064 patients with
history of MI
Simvastatin 80 vs
simvastatin 20
MI, arterial
revascularisation,
stroke, coronary
death
6.7 — — 13.5 1.2% (P 5 .10) 6% with
simvastatin
80 mg (P 5 .10)
106
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CHD, coronary heart disease; CV, cardiovascular; hsCRP, high-sensitivity C-reactive protein; HTN, hypertension; LDL-C, low-density
lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; PEP, primary endpoint; UA, unstable angina.
*In the ALLHAT-LLT, 4S, and HPS studies the primary endpoint (PEP) was defined as all-cause mortality. Only CV-related endpoints are summarized for these studies.
†Baseline LDL-C is intended to denote achieved LDL-C without statin therapy. In some cases, baseline LDL-C was back-estimated from available data.
‡5-year NNT estimated from available data on absolute risk reduction, relative risk reduction, and duration of follow-up.
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Wadhera et al LDL-C and CV morbidity and mortality 481niacin is suggested in patients unable to achieve the desired
LDL-C goal despite statin monotherapy or in patients with
statin intolerance. Use of the Systematic Coronary Risk
Estimation (SCORE) model, validated in European
populations, is recommended for the estimation of
10-year CV risk in populations without established
atherosclerotic CV disease (ASCVD).102 Established
ASCVD (ACS, history of MI, stable angina, coronary or
other arterial revascularization, stroke, transient ischemic
attack or peripheral arterial disease presumed to be of
atherosclerotic origin), diabetes, moderate/severe chronic
kidney disease or a 10-year SCORE $10% establishes
‘‘very high risk’’ with an LDL-C goal of ,70 mg/dL.
‘‘High risk’’ is established by marked elevation of a single
risk factor (e.g., familial dyslipidemia or hypertension) or a
10-year SCORE $5 to ,10% with an LDL-C goal of
,100 mg/dL. Guidance on secondary targets (non-HDL-
C or apoB) is also provided.
ACC/AHA guidelines, 2013
Like the ESC/EAS guidelines, the ACC/AHA guidelines
recommend lifestyle modification as a component of all
lipid-lowering treatment strategies. The ACC/AHA guide-
lines, however, recommend an alternative drug treatment
approach and the new Pooled Cohort Equation for 10-year
risk estimation in primary prevention cohorts. High-intensity
statin therapy is recommended in (1) individuals 21 to
75 years of age with ASCVD; (2) individuals $21 years of
age with LDL-C .190 mg/dL; and (3) individuals 40 to
75 years of age with no ASCVD but diabetes and LDL-C 70
to 189 mg/dL with$ 7.5% 10-year ASCVD risk. Moderate-
intensity statin therapy is recommended in (1) individuals
.75 years of agewithASCVD; (2) individuals 40 to 75 years
of age with no ASCVD but diabetes and LDL-C 70 to 189
mg/dL with ,7.5% 10-year ASCVD risk; and (3) individ-
uals 40 to 75 years of age with no ASCVD or diabetes and
LDL-C 70 to 189 mg/dL with $7.5% 10-year ASCVD
risk.17 These guidelines also suggest that when randomized
control trial evidence demonstrates that nonstatin therapy
further reduces adverse CVevents when added to statin ther-
apy, nonstatin therapy should be considered. A lipid profile is
recommended after initiation of statin therapy, primarily to
ensure adherence, but routine monitoring (e.g., every
6–12 months) is not recommended.
Comparison of ESC/EAS and ACC/AHA guidelines
The ACC/AHA’s emphasis on a strategy of fixed-dose
statin therapy based on risk without titration to pre-defined
LDL-C goals is distinct from the ESC/EAS guidelines. The
authors of the ACC/AHA guidelines decided on this
approach to be consistent with the design of statin
trials, which tested fixed dose (e.g., simvastatin 40 mg),
rather than ‘‘titrate-to-goal’’ strategies. Simplification of the
appropriate drug choice may result in greater treatment
with potent statins, avoiding the well-documented problemsof suboptimal statin dose initiation and limited uptitra-
tion.103–105 A fixed dose strategy eliminates the need for
routine lipid monitoring but raises the importance for
thorough lifestyle and statin adherence evaluations and
discussions at each clinical encounter. Rates of
nonadherence are high, thus it is possible that without lipid
monitoring, nonadherence may be less frequently
identified.106
De-emphasis of achievement of specific LDL-C levels
leaves it unclear whether physicians should consider the
addition of other lipid-lowering treatments in patients with
recalcitrantly high LDL-C despite high-intensity statin
therapy. As discussed in previous sections, the body of
evidence across genetic studies, epidemiologic studies,
animal models, and post-hoc/meta-analyses of trial data
indicate that residual CV risk is associated with achieved
LDL-C. Reported after the publication of both guidelines,
the IMPROVE-IT trial results demonstrated the effective-
ness and outstanding tolerability of ezetimibe. These
findings may shift the focus of future guidelines toward
achievement of specific LDL-C goals (e.g., ,50 mg/dL not
just by statins but also ezetimibe).
A greater number of US patients are expected to qualify
for statin therapy under the 2013 AHA/ACC guidelines
(approximately 12.8 million more between the ages of 40 to
75 years) compared to the National Cholesterol Education
Program Expert Panel on Detection Evaluation and
Treatment of High Blood Cholesterol in Adults Adult
Treatment Panel III (NCEP ATP III) guidelines.107,108 The
vast majority of this expansion in statin treatment would
be based on a 10-year ASCVD risk $7.5%.107,109 A recent
analysis supports this expansion and suggests that treatment
beyond this threshold (even down to $3.0% 10-year
ASCVD risk) would be cost effective.110Next steps in LDL-C-lowering therapeutics
Results from the IMPROVE-IT trial, taken together with
the CTT meta-analysis of statin trials, demonstrate a
continuous relationship between LDL-C lowering and CV
risk reduction down to about 50 mg/dL.73 Whether a
beneficial net efficacy/safety profile can be achieved
when targeting even lower LDL-C levels is unknown, but
evidence suggests this may be a promising strategy for
new drug development. In addition, there is a need for
new LDL-C-lowering therapies for those on maximal statin
therapy and/or ezetimibe who are unable to achieve current
LDL-C goals (e.g., ,70 mg/dL). These therapies may also
be beneficial for patients not able or unwilling to take
statins or other LDL-C-lowering drugs.
Targeting very low LDL-C
Post-hoc analyses of randomized trials consistently
suggest a potential benefit from treatment to LDL-C levels
beyond those currently recommended by guidelines. A
482 Journal of Clinical Lipidology, Vol 10, No 3, June 2016recent meta-analysis of statin trials indicated that
individuals achieving LDL-C levels ,50 mg/dL with statin
therapy had a lower risk of major CV events, but possibly
slightly higher risk of hemorrhagic stroke (although
absolute event rate was low), compared to those achieving
levels between 75 and ,100 mg/dL.111 One trial included
in the meta-analysis (JUPITER), reported no systemic
increase in adverse events in those achieving LDL-C
,50 mg/dL (median follow-up of 2 years).112 In the
PROVE IT-TIMI 22 trial, achieving LDL-C #40 mg/dL
on atorvastatin 80 mg was associated with a lower risk of
major CV events without any increase in adverse
events (mean follow-up of 2 years).113 Another analysis
of JUPITER demonstrated that achieving LDL-C
,30 mg/dL was also not associated with a higher total
adverse event rate; it was, however, associated with more
physician-reported diabetes, hematuria, hepatobiliary
disorders, and insomnia.114
Naturally occurring examples in humans suggest that
good health may coexist with prolonged exposure to very
low LDL-C levels. Umbilical-cord measurements suggest
that fetal growth and development occurs in the setting of
LDL-C ,40 mg/dL.115,116 In individuals with hypobetali-
poproteinemia, lifelong very low levels of LDL-C
(,15 mg/dL) has not been associated with adverse
effects.117 In a report of 2 individuals, both women with
homozygous loss-of-function PCSK9 mutations resulting
in LDL-C #15 mg/dL, subjects appeared to be asymptom-
atic with normal development, intelligence, and ability to
bear healthy children.118,119 Thus, it is possible that the
physiologic range for LDL-C extends to these extremely
low levels. These data provide reassurance for an
acceptable safety profile to pursue research in novel
LDL-C lowering mechanisms to be used in conjunction
with potent statins or potent statins plus ezetimibe.
Novel therapeutic agents
Studies of genetic mutations associated with potentially
beneficial lipid profiles, including lower LDL-C, have led
to the identification of targets for the development of
novel therapeutic agents.120 An example is the PCSK9
inhibitors, alirocumab, evolocumab, and bococizumab.
Circulating PCSK9 increases endosomal and lysosomal
degradation of hepatic LDL receptors resulting in the
decreased ability to clear LDL particles from the
circulation.121 PCSK9 inhibitor-based therapies are fully
human monoclonal antibodies that bind to circulating
PCSK9 resulting in greater numbers of hepatic LDL
receptors.
Alirocumab has been assessed recently in phase III trials
with 75 mg and 150 mg Q2W dosing.122 The recent
ODYSSEY LONG TERM study investigated alirocumab’s
efficacy and safety in 2341 patients. In high CV risk
patients on statins, alirocumab compared with placebo
resulted in a 62% reduction in LDL-C and the incidence
of major CVevents by 48% (P5 .02) in a post-hoc analysiswith 78-week follow-up.123 The ongoing ODYSSEY
OUTCOMES study in approximately 18,000 post-ACS
patients is assessing the impact of adding alirocumab to
statin therapy on major CV events.124
Evolocumab has also recently been evaluated in phase
III trials with 140 mg every 2 weeks (Q2W) and 420 mg
every 4 weeks dosing.122 The recent OSLER I and II
studies assessing efficacy and safety in 4465 patients
demonstrated that evolocumab plus standard therapy
reduced LDL-C by 61% and the incidence of major CV
events by 53% (P 5 .003) compared to standard therapy
alone in a prespecified but exploratory analysis with
1 year follow-up.125 The ongoing FOURIER study in
approximately 27,500 patients with established CV disease
on statin therapy is assessing as its primary endpoint
whether addition of evolocumab reduces the incidence of
major CV events.126
In the OSLER and ODYSSEY LONG TERM studies,
the rate of any adverse events and/or serious adverse
events was similar in patients receiving PCSK9 inhibitors
compared to placebo. The rate of neurocognitive events
was higher in PCSK9 inhibitor groups, although the total
number of events was low.123,125 Rates of newly diag-
nosed diabetes and worsening of preexisting diabetes
were similar.123 A meta-analysis of 24 randomized
control trials demonstrated similar rates of serious
adverse events between patients receiving PCSK9 inhib-
itors compared to those who did not (9.26% vs 7.73%,
P 5 .88).127 Data from the ODYSSEY LONG TERM
study revealed that driving LDL-C levels to ,25 mg/
dL did not increase adverse events compared to
placebo.123
In light of their efficacy and favorable safety profile,
both alirocumab and evolocumab have been approved by
the FDA for use in patients with clinical ASCVD who
require additional LDL-C lowering, and in adult patients
with heterozygous familial hypercholesterolemia already
on maximally tolerated statin therapy.
Another novel pharmacologic approach for LDL-C
lowering is CETP inhibition. CETP shuttles triglycerides
and cholesteryl esters between apoB-containing
lipoproteins and HDL, causing remodeling of circulating
lipoproteins. Potent inhibition of this enzyme dramatically
increases HDL-C and can reduce LDL-C and lipoprotein(a).
The failure of the early CETP inhibitors, torcetrapib (due to
an increased risk of CV death presumably secondary to off-
target effects), dalcetrapib (presumably due to minimal
reductions in LDL-C), and most recently evacetrapib (Phase
III trial stopped early due to low probability of achieving
the primary endpoint) have not fully closed the door on
CETP as a drug target.128–131 The CETP inhibitor, anacetra-
pib, has been shown to increase HDL-C by 140% and
decrease LDL-C by approximately 40% on top of statin
therapy, and is currently undergoing evaluation in the
REVEAL HPS3-TIMI 55 trial.132 Although anacetrapib re-
duces LDL-C, it does increase small (and potentially more
atherogenic) LDL particles.133
Table 4 Novel LDL-C lowering therapies and their respective CV outcomes trials
Drug type Trial name Study population Planned enrollment Estimated completion
PCSK9 inhibitors
Evolocumab FOURIER Established CV disease 27,500 February, 2018
Alirocumab ODYSSEY OUTCOMES Recent ACS 18,600 February, 2018
Bococizumab SPIRE I High risk for CV events 17,000 June, 2018
Bococizumab SPIRE II High risk for CV events 9,000 March, 2018
CETP inhibitor
Anacetrapib REVEAL Established CV disease 30,600 January, 2017
ACS, acute coronary syndromes; CETP, cholesterol ester transfer protein; CV, cardiovascular; PCSK9, proprotein convertase subtilisin/kexin type 9.
Source: clinicaltrials.gov.
Wadhera et al LDL-C and CV morbidity and mortality 483LDL-C lowering through these therapeutic agents offers
a novel strategy to reduce residual risk of atherosclerotic
CV events, especially after recent failures of treatments
aimed at other targets, including HDL-C and lipoprotein-
associated phospholipase A2.
134 Data from CV outcomes
trials of novel, potent LDL-C lowering drugs will provide
insight into the net balance of benefits, and risks associated
with even greater LDL-C reduction and lower levels of
achieved LDL-C (Table 4).Population-level and health-system
initiatives
Population-level and health-system changes could have an
immense influence on improving lifestyle behaviors, choles-
terol screening, and access to providers and evidence-based
therapies. As previously discussed, the Finnish experience is
just one example of an effective population intervention
guiding public health policy but illustrates the profound
population effect (i.e., mean total cholesterol reduction
60 mg/dL) local and national policies can achieve.
Lifestyle initiatives
Long-term improvements in diet and exercise through
behavioral interventions may significantly reduce LDL-C,
which, when initiated in children and adolescents, might
result in dramatic reductions in the incidence of CV events
later in life. In Bogota, Colombia, a preschool-based
intervention targeting 1200 children improved knowledge,
attitudes, and habits related to healthy eating and physical
activity at 1 year. Three years later, further improvements
were seen in the same endpoints in this cohort.135 This
suggests that interventions targeting periods of behavioral
malleability (e.g., ages 3 to 5 years) can have beneficial,
sustained impacts on lifestyle habits.
Disease awareness
Lack of awareness is a significant barrier to the appro-
priate treatment of hypercholesterolemia. The MinnesotaHeart Survey demonstrated that from 2000–2002 over half of
men and women at or above moderate risk of CHD were
unaware of their elevated cholesterol.136 Data from National
Health and Nutrition Examination Survey during 1999–2002
revealed that only 63% of US adults had their cholesterol
screened within 5 years (as recommended by the NCEP
guidelines).137 Furthermore, data from both studies demon-
strated that a high proportion of individuals who were aware
of their elevated cholesterol levels were not receiving
treatment. Policy efforts must focus on better screening
with appropriate triage to medical providers for at risk
patients. TheAffordableCareAct not only expands health in-
surance coverage, but also promotes preventative screening,
including for lipid disorders.
Medication adherence
Medication nonadherence compromises the effective-
ness of proven therapies. Registry data of post-MI patients
from a large panel of US hospitals from 2003–2009
indicate that approximately only one-third of patients
were discharged with an intensive statin.138 Recent data
of those insured under a large commercial plan showed
that just 49% of post-MI patients were adherent to
statins at 1-year follow-up.139 In England in 2007, the
rate at which statin prescriptions were filled for patients
with established CV disease was somewhat higher at
66%–85%.16
Causes of statin underutilization are likely multifactorial.
A number of patient factors have been associated with statin
adherence.106 Age predicts nonadherence in a bimodal
fashion, with the oldest (.70) and youngest (,50) being
the poorest adherers.140,141 Patients that are non-Caucasian,
low-income, female, or smoke are less likely to be compliant
with lipid-lowering drugs, although these demographics are
not always reliable predictors.142,143 Patients with a history
of CHD are up to 3 times more likely to be adherent than
thosewithout a history of CHD.144,145 Limited income, poly-
pharmacy, dementia, and depression and/or anxiety have all
been shown to increase nonadherence.146,147 Health system–
related issues also influence adherence. Medicaid patients
are approximately 43% less likely to have high statin
484 Journal of Clinical Lipidology, Vol 10, No 3, June 2016persistence, supporting that individuals or families with low
incomes and limited resources may be prone to nonadher-
ence.148 High insurance copayments also diminish statin
adherence.149 Medication expense is also an important
factor. In the USAGE study, cost prompted nearly half of
patients to switch statins.150
Patient adherence can be improved by interventions that
focus on extended care with nonphysician providers, better
follow-up, and increased contact with physicians.151
Enhancing the physician-patient communication axis and
providing counseling can improve statin adherence.152
Practical interventions such as medication reminders and
improved patient education are also effective.153 The use
of combination ‘‘polypills’’ may also help simplify
complex medication regimens.154
Provider behavior also contributes to suboptimal statin
use. Evidence suggests that providers often fail to start and
uptitrate statins appropriately.103–105,138 This may be
secondary to reluctance to re-evaluate long-standing
treatments, mislabeling patients as ‘‘statin intolerant’’ or
‘‘allergic’’, and busy workflows that interfere with the
required time and attention necessary to review and
optimize medication regimens. As previously suggested,
providers may not provide effective education on statin
indications, proper dosing, tolerability, and safety.103,105,138
In addition, providers may underestimate the success rate of
statin rechallenges. In an observational study of clinical
practices from a single academic institution over 9 years,
17% of 107,835 patients discontinued statin use due to
events labeled as ‘‘statin related’’. Of patients who
discontinued statins and were rechallenged over the
subsequent 12 months, greater than 90% eventually
tolerated statin use.155
Technological solutions
Health system barriers can propagate gaps in chronic
disease care. New payment models that reward
coordination and quality are being used by the Center for
Medicare and Medicaid Services. These models depend on
electronic health records (EHRs) to provide the tools
necessary to track and improve quality of care. EHR
adoption and use for a broader array of tasks is incentivized
by the meaningful use criteria established by the HITECH
Act. Studies already have demonstrated the impact of
EHR-based performance feedback coupled with a quality
improvement tool for LDL-C reduction. For example, use
of EHRs at Kaiser Permanente was associated with
statistically significant improvements in treatment
intensification as well as downstream LDL-C reductions.156
This was attributed to greater alignment with quality
measures and clinical guidelines as well as increased
availability of information and decision support through
the EHR. Other technological interventions such as
telemedicine have been shown to improve outcomes in
chronic conditions (i.e., diabetes) and are currently
undergoing evaluation for dyslipidemia.157 EHRs and othertechnological initiatives have the potential to support
provider decision-making, patient self-management, and
quality improvement.158
Overall, hypercholesterolemia is best treated through a
multi-faceted strategy similar to other public health issues,
such as tobacco use. LDL-C reduction will be best achieved
not only by continued drug development, but by
comprehensive public health initiatives (e.g., nutritional
content reporting in restaurants, food product labeling),
cholesterol screening, promotion of healthy lifestyles, and
technological and health system advances that facilitate and
promote value-based care.Conclusion
CV disease causes significant worldwide morbidity and
mortality and contributes to substantial health care spending.
The treatment of hypercholesterolemia, and specifically
elevated LDL-C, represents an established strategy to
diminish incident CVevents andmortality. Numerous studies
have established the continuous, graded, benefit conferred by
LDL-C reduction on CV event risk and mortality. Future
studies should focus on the impact and safety of targeting
‘‘very-low’’ LDL-C, earlier initiation of LDL-C–lowering
interventions, the development and impact of novel
therapeutic agents, as well as the use of evidence-based
policy and regulatory initiatives to reduce environmental
causes of elevated LDL-C on a population level.Acknowledgments
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